Belite Bio Cash Flow Statement
NASDAQ: BLTEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
154.49+1.97 (+1.29%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Belite Bio free cash flow
In fiscal 2025, Belite Bio generated -$37.0 million of operating cash flow and spent $71,000 on capital expenditures. That left free cash flow of -$37.1 million.
Summary generated from market data by MetaCap's automated system. Methodology
Belite Bio cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 |
|---|---|---|---|---|---|---|
| Net Income | -77.61M | -36.14M | -31.63M | -12.65M | -9.67M | -5.75M |
| Net Income growth (YoY) | — | — | — | — | — | — |
| Depreciation & Amortization | 172.00K | 164.00K | 139.00K | 64.00K | 30.00K | 17.00K |
| Stock-Based Compensation | 38.92M | 8.99M | 3.82M | 1.48M | 1.53M | 1.36M |
| Change in Working Capital | -768.00K | -1.11M | -3.52M | — | — | — |
| Operating Cash Flow | -36.99M | -29.23M | -29.84M | -11.46M | -7.47M | -4.44M |
| Capital Expenditures | -71.00K | -116.00K | -63.00K | -394.00K | -74.00K | — |
| Investing Cash Flow | -305.11M | -110.57M | -63.00K | -394.00K | -56.00K | -20.00K |
| Financing Cash Flow | 663.23M | 83.59M | 75.96M | 36.96M | -583.00K | 28.06M |
| Net Change in Cash | 321.25M | -56.48M | 46.07M | 24.75M | -8.27M | 23.60M |
| Free Cash Flow | -37.06M | -29.35M | -29.90M | -11.85M | -7.55M | -4.44M |
This table shows 6 annual periods of Belite Bio's cash flow statement, from FY 2025 back to FY 2020, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow BLTE's reporting calendar. What is a cash flow statement?